ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medford, A.R.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medford, A.R.L.
Eur Respir J 2004; 24:1070
Copyright ©ERS Journals Ltd 2004

Combination therapy with maintenance budesonide and formoterol in COPD

A.R.L. Medford

Dept of Respiratory Medicine, Southmead Hospital, Bristol, UK

Received: July 6, 2004
Accepted July 14, 2004

To the Editors:

Calverley et al. 1 provide further evidence for combination therapy with inhaled corticosteroids and long-acting ß-agonists in severe chronic obstructive pulmonary disease (COPD) as maintenance therapy. In addition, a previous study, also confirming such benefit, showed an advantage for monotherapy with fluticasone in reducing exacerbations 2. The study by Calverley et al. 1 did not show a benefit for budesonide monotherapy in exacerbation reductions. Does monotherapy with inhaled steroids reduce exacerbations in severe COPD?

The conclusion that "additional clinical benefit when combined in a single inhaler" would surely be further strengthened by assessing the effectiveness of the fixed-dose single inhaler combination against the same drugs in separate inhalers? As there are sound cellular reasons for combining these two classes of drug 3, would there not be a potential advantage in the use of these two drugs as separate inhalers to allow greater dose flexibility, although this is of greater relevance in asthma? Or, if fixed-dose combinations are superior to separate inhalers taken together, then would this also be an important finding to favour the former?

References

  1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912–919.[Abstract/Free Full Text]
  2. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449–456.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  3. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182–191.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medford, A.R.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medford, A.R.L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS